{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:26:43Z","timestamp":1720571203844},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"DOI":"10.7759\/cureus.64127","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:34:33Z","timestamp":1720514073000},"source":"Crossref","is-referenced-by-count":0,"title":["Cases of Fabry Disease in Which Pathogenic Variants Are Not Detected in Parent-Child Pairs"],"prefix":"10.7759","author":[{"given":"Naoki","family":"Akeho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Muta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Torigoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineaki","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Japanese Society for Inherited Metabolic Diseases. Practical guideline for the management of Fabry disease 2020. (Article in Japanese). (2020). https.\/\/jsimd.net\/pdf\/fabry2020.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders M","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021, 81:635-45. 10.1007\/s40265-021-01486-1","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijns9020031","article-title":"Newborn screening for Fabry disease: current status of knowledge","volume":"9","author":"Gragnaniello V","year":"2023","unstructured":"Gragnaniello V, Burlina AP, Commone A, et al.. Newborn screening for Fabry disease: current status of knowledge. Int J Neonatal Screen. 2023, 9:31. 10.3390\/ijns9020031","journal-title":"Int J Neonatal Screen"},{"key":"ref4","unstructured":"The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. GLA. (2023). Accessed. June 21, 2023: https:\/\/www.hgmd.cf.ac.uk\/ac\/gene.php?gene=gla."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz A","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al.. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018, 123:416-27. 10.1016\/j.ymgme.2018.02.014","journal-title":"Mol Genet Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu WL","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, et al.. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009, 30:1397-405. 10.1002\/humu.21074","journal-title":"Hum Mutat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira S","year":"2015","unstructured":"Ferreira S, Ortiz A, Germain DP, et al.. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol Genet Metab. 2015, 114:248-58. 10.1016\/j.ymgme.2014.11.004","journal-title":"Mol Genet Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313y is not clinically relevant for Fabry disease","volume":"7","author":"Niemann M","year":"2013","unstructured":"Niemann M, Rolfs A, Giese A, et al.. Lyso-Gb3 indicates that the alpha-galactosidase A mutation D313y is not clinically relevant for Fabry disease. JIMD Rep. 2013, 7:99-102. 10.1007\/8904_2012_154","journal-title":"JIMD Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol L","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014, 51:1-9. 10.1136\/jmedgenet-2013-101857","journal-title":"J Med Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak A","year":"2022","unstructured":"Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet. 2022, 59:287-93. 10.1136\/jmedgenet-2020-107338","journal-title":"J Med Genet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1229088","article-title":"Novel enhancer mediates the RPL36A-HNRNPH2 readthrough loci and GLA gene expressions associated with Fabry disease","volume":"14","author":"Al-Obaide MA","year":"2023","unstructured":"Al-Obaide MA, Islam S, Al-Obaidi I, Vasylyeva TL. Novel enhancer mediates the RPL36A-HNRNPH2 readthrough loci and GLA gene expressions associated with Fabry disease. Front Genet. 2023, 14:1229088. 10.3389\/fgene.2023.1229088","journal-title":"Front Genet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01019-3","article-title":"DNA methylation impact on Fabry disease","volume":"13","author":"Di Risi T","year":"2021","unstructured":"Di Risi T, Vinciguerra R, Cuomo M, et al.. DNA methylation impact on Fabry disease. Clin Epigenetics. 2021, 13:24. 10.1186\/s13148-021-01019-3","journal-title":"Clin Epigenetics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/271894-cases-of-fabry-disease-in-which-pathogenic-variants-are-not-detected-in-parent-child-pairs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:34:39Z","timestamp":1720514079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/271894-cases-of-fabry-disease-in-which-pathogenic-variants-are-not-detected-in-parent-child-pairs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.64127","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}